who we are

Dedicated to results

The NellOne Therapeutics is passionate about its work to pioneer advances in the field of tissue regeneration, developed over the course of many years of scientific research and exploration. Our highly experienced team is committed to improving outcomes for millions of patients across the world, and creating a successful business that truly makes a difference.

Management

CEO

Bill Malkes

Serial entrepreneur Bill Malkes was appointed Chief Executive Officer of NellOne Therapeutics in April 2020. He previously co-founded and led GRIDSMART Technologies Inc, a global intelligent transportation solutions business, which was sold for $87 million in 2019. Under Malkes’ leadership, the business grew to be the second largest in its space, and expanded to 22 countries around the world. Prior to GRIDSMART, Malkes held a number of senior leadership and advisory roles in technology and healthcare businesses including Health Care Solutions, ASIC International, Tradewind Technologies and Learning Technology Systems.

CSO

Dr. Cymbeline Culiat

Dr. Cymbeline (Bem) Culiat studied the genetic and molecular basis of early mammalian development for a decade as a senior scientist at Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (1999-2009). Her research elucidated the role of the NELL1 protein in promoting growth and maturation of the musculoskeletal and cardiovascular systems. This discovery is the foundation on which NellOne Therapeutics (NellOne) was established in 2008. Dr. Culiat is the inventor on several patents issued in seven countries, on the veterinary and human applications of NELL1 as a novel therapeutic for wound healing and cardiovascular disorders. These patents are exclusively licensed worldwide to NellOne, which Dr. Culiat co-founded with CEO Tracy Warren (General Partner, Battelle Ventures and Astarte Ventures). Bem currently serves as Chief Scientific Officer.

title

Tracy Warren

An investor, executive, and entrepreneur, Ms. Warren co-founded NellOne Therapeutics, a soft-tissue regenerative medicine company based on the NELL1 gene based on work initiated at Oak Ridge National Laboratory by her co-founder, Dr. Cymbeline Culiat. As founding CEO, she leads the company’s efforts with respect to strategy, fundraising, business development and licensing for its equine and human therapies.

Having spent over a decade commercializing technologies from nation’s leading institutions, Tracy serves on the Boards of Children’s Research Institute (CRI) at Children’s National Medical Center (Washington, DC) and Clemson University Research Foundation, and is a member of the Business Advisory Council to the Sheikh Zayed Institute for Pediatric Surgical Innovation. In addition to her investment activities, she also provides early-stage leadership to other businesses, currently serving as a general partner of Astarte Ventures, an early stage venture firm focused exclusively on women’s and children’s health and wellbeing.

Title

Shannon Eaker

Shannon received his PhD from the University of Tennessee, Knoxville in Biochemistry, Cellular and Molecular Biology. His expertise is around T-cell, HSC, and ES/iPSC cell biology, and has been with Cytiva (formerly GE Healthcare) Cell and Gene Therapy for over 10 years. He is a member of the International Society for Cell Therapy (ISCT) Process and Product Development (PPD) committee, and has authored numerous papers within the field of cell biology and manufacturing. He is currently the Technical Leader within Cytiva’s Cell and Gene Therapy Enterprise Solutions group. Shannon lives with his wife and 2 kids in Knoxville, TN.

Partner with us

Join us in plotting a new future for regenerative medicine, and help us in our work to revolutionize the treatment of major traumatic wounds in soft tissue.